Truist Securities Reiterates Buy on Xencor, Raises Price Target to $29

9/28/2026
Impact: 70
Healthcare

Truist Securities analyst Gregory Renza has reiterated a Buy rating on Xencor (NASDAQ: XNCR) and increased the price target from $27 to $29.

AI summary, not financial advice

Share: